ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - леналидомид - Множествена миелома - Имуносупресори - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) е показан за лечение на възрастни пациенти с по-рано нелекувана множествена миеломой, на които не се разчита за трансплантация. Акорд леналидомид в комбинация с дексаметазоном е показан за лечение на множествена миеломы при възрастни пациенти, които са получили най-малко един курс на терапия. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - Карцином, сквамозна клетка - Антинеопластични средства - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

বুলগেরিয়া - বুলগেরিয় - БАБХ (Българска агенция по безопасност на храните)

intervet international b.v - Бордетеллы bronchiseptica, жив щам-c2; вируса на кучешки, parainfluenza, жив щам Корнел - лиофилизат и разтворител за капки за нос - ≥ 10 на степен 8 - 10 на степен 9, 7 cfu; ≥ 10 на степен 3 - 10 на степен 5, 8 tcid50 - кучета

ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - рекомбинантный вирус везикулярного стоматит (щам Индиана) със заличаването на плик гликопротеин, заменени от Ебола Заир (щам киквите 1995) повърхностен гликопротеин - Хеморагична Треска Ебола - Ваксини - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. Използването на ervebo трябва да бъде в съответствие с официалните препоръки.

ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

bayer healthcare ag - прадофлоксацин - Антибактериални средства за системна употреба - Кучета - Куче: инфекции на кожата и меките тъкани, аз. повърхностни и дълбоки пиодермии и раневых инфекции, причинени от грамположительными микроорганизми, обикновено стафилокок ПТ. и streptococcus ПТ. и грам-отрицателни микроорганизми, като например е. коли, синегнойная ПТ. и Протеус ПТ. Инфекции на пикочните пътища, причинени от грам-отрицателни бактерии, като например бактерии от семейство enterobacteriaceae, e. Е. коли, enterobacter ѕрр. , Клебсиелла ПТ. и Протеус ПТ. , Синегнойная ПТ. и грам положителни организми, като правило, staphylococcus ПТ. Инфекция на венците и тъканите на пародонта, причинени от анаеробни организми, например, porphyromonas ПТ. , Превотелл ПТ. ; fusobacterium ѕрр. , Эйкенеллу ПТ. и capnophilic бактерии, като capnocytophaga ПТ. , , cats:, infections of the respiratory tract caused by gram-negative organisms such as pasteurella spp. , Коли и pseudomonas ПТ. и грамположительные микроорганизми, като streptococcus ПТ. и стафилокок ПТ.

ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

bavarian nordic a/s - холерный вибрион, щам и ИЗРАВНИТЕЛНИТЕ 103-hgr за да живеят - холера - Ваксини - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. Тази ваксина трябва да се използва в съответствие с официалните препоръки.

ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Хеморагична Треска Ебола - Ваксини - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - Хеморагична Треска Ебола - Ваксини - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - Левкемия, миелоиден, остър - Антинеопластични средства - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - Други лекарства противоанемические - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.